Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
4D Molecular Therapeutics (FDMT) just unveiled an announcement.
4D Molecular Therapeutics, Inc. is set to unveil interim data from its PRISM clinical trial for 4D-150, a treatment for wet age-related macular degeneration, at a medical conference in September 2024. Details on the presentation will align with the company’s second-quarter financial report in August 2024. The 52-week analyses for the trial’s cohorts are on track for release in February 2025.
For detailed information about FDMT stock, go to TipRanks’ Stock Analysis page.